TING Einweg-Enterale Fütterungssonde

Grundinformation

• Verfügbar ab:
• English
• Deutsche

EarlyTect Colon Cancer Test is a groundbreaking product in the field of colorectal cancer screening. It has earned approval from the Korea Ministry of Food and Drug Safety after successful clinical trials at renowned medical centers such as Yonsei Medical Center, Severance Hospital, and Severance Check-up Center. The trials involved 585 men and women aged 30 to 80 who were eligible subjects for the test. The results of these trials showed an impressive accuracy rate, with a 90% sensitivity and specificity in diagnosing colorectal cancer.

The EarlyTect Colon Cancer Test utilizes a qualitative real-time PCR method to measure the presence of methylated Syndecan-2, a clinically significant biomarker associated with precancerous lesions of colorectal cancer, in stool DNA. With this innovative approach, the test is able to detect and diagnose colorectal cancer at an early stage, potentially saving lives through early intervention.

It is important to note that the EarlyTect Colon Cancer Test is not intended to confirm the presence of colorectal cancer itself. Instead, it serves as a valuable tool to detect the existence of CRC or precancerous lesions. Therefore, if a subject receives a positive result from the test, further medical evaluation is necessary to confirm the presence of colorectal cancer or its precancerous stages.

The product conforms to the following standards:

- Cancer Type: Colorectal Cancer
- Subject: Asymptomatic individuals undergoing colorectal cancer screening
- Biomarker: SDC2 methylation

In terms of pricing and transaction conditions, they are negotiable based on individual requirements. To proceed with a purchase or gather more information, we kindly request that you submit a quote request, and our team will respond promptly.